Reduction in CD4 central memory T-cell subset in costimulation modulator abatacept-treated patients with recent-onset type 1 diabetes is associated with slower C-peptide decline

Diabetes

Volumn 63, Issue 10, 2014, Pages 3449-3457

  Orban, Tihamer ^a   Beam, Craig A ^b   Xu, Ping ^b   Moore, Keith ^c   Jiang, Qi ^c   Deng, Jun ^c   Muller, Sarah ^b   Gottlieb, Peter ^d   Spain, Lisa ^e   Peakman, Mark ^f,g  

^a JOSLIN DIABETES CENTER   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c David H Murdock Research Institute   (United States)

^d UNIVERSITY OF COLORADO DENVER   (United States)

^e NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^f National in Stitutes of Health   (United States)

^g KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; C PEPTIDE; CD45RO ANTIGEN; L SELECTIN; PLACEBO; ANTIBODY CONJUGATE; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; B LYMPHOCYTE; CD4 LYMPHOCYTE COUNT; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CHILD; CLINICAL OBSERVATION; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE MARKER; DRUG EFFECT; DRUG MEGADOSE; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MEMORY T LYMPHOCYTE; MIDDLE AGED; MONOCYTE; MYELOID DENDRITIC CELL; NATURAL KILLER T CELL; PHASE 2 CLINICAL TRIAL (TOPIC); PLASMACYTOID DENDRITIC CELL; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ADOLESCENT; BLOOD; CONTROLLED CLINICAL TRIAL; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; PHASE 2 CLINICAL TRIAL; T LYMPHOCYTE SUBPOPULATION; YOUNG ADULT;

ADOLESCENT; ADULT; C-PEPTIDE; CD4-POSITIVE T-LYMPHOCYTES; CHILD; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; IMMUNOCONJUGATES; IMMUNOLOGIC MEMORY; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; T-LYMPHOCYTE SUBSETS; YOUNG ADULT;

EID: 84907487451     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-0047     Document Type: Article

References (20)

1. Herold KC, Vignali DA, Cooke A, Bluestone JA. Type 1 diabetes: Translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol 2013;13:243-256
2. Stiller CR, Dupré J, Gent M, et al. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 1984; 223:1362-1367
3. Harrison LC, Colman PG, Dean B, Baxter R, Martin FI. Increase in remission rate in newly diagnosed type I diabetic subjects treated with azathioprine. Diabetes 1985;34:1306-1308
4. Orban T, Farkas K, Jalahej H, et al. Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. J Autoimmun 2010;34:408-415
5. Wherrett DK, Bundy B, Becker DJ, et al.; Type 1 Diabetes TrialNet GAD Study Group. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 2011;378:319-327
6. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002;346:1692-1698
7. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005;352:2598-2608
8. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al.; Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009;361:2143-2152
9. Orban T, Bundy B, Becker DJ, et al.; Type 1 Diabetes TrialNet Abatacept Study Group. Co-stimulation modulation with abatacept in patients with recentonset type 1 diabetes: A randomised, double-blind, placebo-controlled trial. Lancet 2011;378:412-419
10. Matthews JB, Staeva TP, Bernstein PL, Peakman M, von Herrath M; ITNJDRF Type 1 Diabetes Combination Therapy Assessment Group. Developing combination immunotherapies for type 1 diabetes: Recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group. Clin Exp Immunol 2010;160:176-184
11. Roep BO, Peakman M. Surrogate end points in the design of immunotherapy trials: Emerging lessons from type 1 diabetes. Nat Rev Immunol 2010;10:145-152
12. Bluestone JA, St Clair EW, Turka LA. CTLA4lg: Bridging the basic immunology with clinical application. Immunity 2006;24:233-238
13. Marelli-Berg FM, Okkenhaug K, Miranda V. A two-signal model for T cell trafficking. Trends Immunol 2007;28:267-273
14. Farber DL, Yudanin NA, Restifo NP. Human memory T cells: Generation, compartmentalization and homeostasis. Nat Rev Immunol 2014;14:24-35
15. Lozanoska-Ochser B, Klein NJ, Huang GC, Alvarez RA, Peakman M. Expression of CD86 on human islet endothelial cells facilitates T cell adhesion and migration. J Immunol 2008;181:6109-6116
16. Scarsi M, Ziglioli T, Airò P. Decreased circulating CD28-negative T cells in patients with rheumatoid arthritis treated with abatacept are correlated with clinical response. J Rheumatol 2010;37:911-916
17. Scarsi M, Ziglioli T, Airò P. Baseline numbers of circulating CD28-negative T cells may predict clinical response to abatacept in patients with rheumatoid arthritis. J Rheumatol 2011;38:2105-2111
18. Álvarez-Quiroga C, Abud-Mendoza C, Doníz-Padilla L, et al. CTLA-4-lg therapy diminishes the frequency but enhances the function of Treg cells in patients with rheumatoid arthritis. J Clin Immunol 2011;31:588-595
19. Herold KC, Pescovitz MD, McGee P, et al.; Type 1 Diabetes TrialNet Anti-CD20 Study Group. Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes. J Immunol 2011;187:1998 -2005
20. Cernea S, Herald KC. Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodies. Clin Immunol 2010;134:121-129